A new test to indicate which people are most at risk from life-threatening allergic reactions has been developed by British scientists.
The procedure measures levels of an enzyme in the blood which is involved in allergic reactions that can cause potentially fatal anaphylactic shock.
Medics hope the test could become the definitive, gold standard test for the diagnosis of severe allergic reactions across the world.
One in three Britons suffers from an allergy and the number of cases is rising by five per cent every year.
It was developed by the University of Southampton’s Dr Andrew Walls working with doctors at Southampton General Hospital to help combat a rise in serious allergic reactions to such things as peanuts.
‘Allergic reactions to drugs are increasingly common and reactions to food such as peanuts, tree nuts and fruit are also a concern, particularly in children and adolescents,’ said Dr Walls, a reader in immunopharmacology.
‘But reliable tests for establishing the risk of a reaction have not been available, leaving patients vulnerable to serious reactions in the future.’
Levels of an enzyme called CPA3 are considerably higher in the blood of people who are prone to life-threatening allergic reactions compared with those who are not.
The level of enzyme can increase rapidly within minutes of the onset of serious allergic reactions, known as anaphylactic shock, and remain elevated for more than a day afterwards.
Using materials developed over a period of years in his research lab, Dr Walls has created a technique to measure these levels in patients and find out who is most at risk.
He said: ‘The development of this test should help to determine the proportion of people with a specific allergy who may be at risk of a life-threatening reaction.
‘This advance allows clinicians to be able to understand the vulnerability of these patients, and either ensure they avoid the problem trigger, or provide them with an injection device so that they can self-administer a drug to fight the onset of a shock, vastly reducing their chances of continued serious attacks.’
Dr Mich Lajeunesse, a consultant paediatric immunologist and a member of the clinical research team, said the test will drastically alter the way doctors diagnose.
‘Severe allergic reactions are frequently overlooked by doctors who call it severe asthma instead,’ he said.
‘This test will help doctors recognise these reactions and provide patients with better aftercare and prevention of future allergic reactions.’
He added: If it proves to be as useful as the early trials suggest, it is likely to become the gold standard for diagnosis of severe allergic reactions around the world.’
The research was funded by the National Institute for Health Research.